human epidermal growth factor 2 negative carcinoma of breast
Showing 1 - 20 of 20
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Boston (Eribulin, Adriamycin,
Active, not recruiting
- Inflammatory Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Eribulin
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 28, 2022
Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Bronx (Rebastinib,
Terminated
- Breast Cancer
- +4 more
- Rebastinib
- +2 more
-
Bronx, New YorkMontefiore Medical Center
Mar 23, 2022
Breast Cancer, Estrogen Receptor Positive Breast Cancer, Node-negative Breast Cancer Trial in Boston (Breast Cancer Treatment
Completed
- Breast Cancer
- +3 more
- Breast Cancer Treatment Decision Aid for women 70+
- Usual Care
-
Boston, Massachusetts
- +1 more
Mar 10, 2022
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Recruiting
- Metastatic Breast Cancer
- +2 more
- Palbociclib
- +2 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center
Jan 17, 2022
Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Germany
Active, not recruiting
- Breast Cancer
- +2 more
- Palbociclib
- +4 more
-
Aachen, Germany
- +69 more
Dec 1, 2021
Tumors, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Worldwide (niraparib,
Completed
- Neoplasms, Breast
- +5 more
- niraparib
- Physician's choice
-
Tucson, Arizona
- +103 more
Nov 2, 2021
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer Trial in Amsterdam (Paclitaxel,
Completed
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Metastatic Breast Cancer
- Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
-
Amsterdam, NetherlandsBOOG Study Center
Jan 16, 2020
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial (Oral NVB Metronomic, Oral NVB Weekly)
Not yet recruiting
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Oral NVB Metronomic
- Oral NVB Weekly
- (no location specified)
Feb 23, 2019
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer Trial
Terminated
- Estrogen Receptor-positive Breast Cancer
- +6 more
- anastrozole
- +2 more
-
Tucson, ArizonaArizona Cancer Center
Jul 23, 2018
Radiotherapy Alternates Human Epidermal Growth Factor 2
Suspended
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
-
Qingdao, Shandong, ChinaQingdao Central Hospital, Qingdao Cancer Hospital
Feb 13, 2018
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast
Terminated
- Estrogen Receptor Negative Breast Cancer
- +5 more
- cisplatin
- +4 more
-
Birmingham, Alabama
- +15 more
May 22, 2017
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Italy (Bevacizumab and eribulin)
Unknown status
- Metastatic Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Bevacizumab and eribulin
-
Cremona, Italy
- +16 more
Jun 14, 2016
Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Tumor Trial in Italy (Everolimus, Exemestane, Fulvestrant)
Unknown status
- Metastatic Breast Cancer
- +4 more
- Everolimus
- +2 more
-
Asti, Italy
- +40 more
Jun 14, 2016
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer Trial in Tucson (drug,
Completed
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- +4 more
- paclitaxel
- +3 more
-
Tucson, ArizonaArizona Cancer Center
Apr 20, 2016
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Trial in Italy (Metformin + Myocet + Cyclophosphamide, Myocet +
Completed
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Metformin + Myocet + Cyclophosphamide
- Myocet + Cyclophosphamide
-
Cesena, FC, Italy
- +24 more
Dec 31, 2015
XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B
Unknown status
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
-
Guangzhou, Guangdong, ChinaGuangdong Academy of Medical Sciences
Jan 28, 2013